This page contains a Flash digital edition of a book.
Characterisation


References 1. Crommelin D et al. The similarity question for biologicals and non-biological complex drugs. Eur J Pharmaceut Sci 2015;76:10–17.


2. Macdougall I. Evolution of iv iron compounds over the last century. J Renal Care 2009;35:8–13.


3. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 2008;6(3- 4):93–102.


4. Okam M et al. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol 2012;87(11): 123–4.


5. Roth S et al. Comparative toxicity and cell-tissue distribution study on nanoparticular iron complexes using avian embryos and HepG2-cells. Transl Res 2008;151(1):36–44.


6. Jahn M et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharmaceut Biopharmaceuti 2011;78(3):480–91.


7. Fütterer S et al. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharmaceut Biomed Analysis 2013;86:151–60.


8. Neiser S et al. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals 2015;28(4):615–35.


9. Stein J, Dignass A, Chow KU. (2012): Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 2012;28(2):241–3.


10. Toblli JE et al. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets 2012;11(1):66–78.


11. Borchard G; Flühmann B; Mühlebach S. Nanoparticle iron medicinal products - Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regul Toxicol Pharmacol 2012;64(2):324–8.


12. European Medicines Agency. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. EMA/CHMP/ SWP/100094/2011. www.ema.europa.eu/docs/ en_GB/document_library/Scientific_ guideline/2011/04/WC500105048.pdf (accessed 20 January 2016).


13. European Medicines Agency. Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. EMA/ CHMP/806058/2009/Rev. 02. www.ema.europa. eu/docs/en_GB/document_library/Scientific_ guideline/2013/03/WC500140351.pdf (accessed 20 January 2016).


14. European Medicines Agency. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. EMA/CHMP/ SWP/620008/2012. www.ema.europa.eu/docs/ en_GB/document_library/Scientific_ guideline/2015/03/WC500184922.pdf (accessed 20 January 2016).


15. Zhang X-M et al. Determination of liposomal encapsulation efficiency using proton NMR spectroscopy. Chem Phys Lipids 2004;127(1):1 13–20.


16. Kudasheva D et al. Structure of carbohydrate- bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem 2004;98(11): 1757–69.


17. Schwertmann U, Cornell RM. Iron oxides in the laboratory. In: Preparation and Characterization (Fürstner A ed) 2nd Edition. Weinheim Wiley-VCH 2002;14–25.


18. Patel M, Ramavataram DVSS. Non transferrin bound iron: nature, manifestations and analytical approaches for estimation. Indian J Clin Biochem 2012;27:322–32.


19. Koskenkorva-Frank T et al. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radical Biol Med 2013;65:1174–94.


20. Esposito B et al. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002;32(Suppl 1):42–9.


21. Jahn M et al. CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA. Electrophoresis 2007;28(14):2424–9.


22. van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dialysis Transplant 2004;19(3):561–65.


23. Balakrishnan V et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 2009;39(6):489–96.


24. Spicher K et al. Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver. Regul Toxicol Pharmacol 2015;73(1):65–72.


www.hospitalpharmacyeurope.com


13


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24